In case you missed the Citrus Development and Research Foundation (CRDF) hosted Peptide Seminar, see it here.
Elemental Enzymes has obtained a patent for a natural peptide solution to treat citrus greening disease. Read more here in the Citrus Industry News.
Florida growers hope peptide treatments a breakthrough in fight against citrus greening.
“In addition to lowering bacterial levels, the trials showed Vismax resulted in 39% more new leaf growth on citrus trees and increased fruit production by about 20%, up to 52% in some cases,” Thompson said.
Low Volume Spray Drones: Using innovative technology to drive agriculture product development
Through the use of an ultra-low volume spray drone, EE products are applied to strip trials. Water-Flux technology increases the water retention and efficiency in the plant which helps maintain photosynthesis and growth under both heat and drought stresses. Hat’s off to David Iseman at Elemental Enzymes for the coordination of the use of the spray drone and video capturing of the application using a second drone.
Elemental Enzymes featured as the MOBIO Breakthrough of the Month
Elemental Enzymes was featured this September on MOBIO’s virtual presentation series Breakthrough of the Month. With MOBIO, Dr. Brian Thompson, CEO, discussed Elemental Enzymes and our novel approach to using enzymes and peptides to improve plant health, performance, and yield. View the poster here.
Watch Brian Thompson, CEO, on Crusonia Conversations
On Septemeber 16th, Elemental Enzymes co-founder and CEO Brian Thompson joined Vonnie Estes, VP of Technology at the Produce Marketing Association, for an in-depth discussion as part of the Crusonia Conversations series.
Hear what Brian had to say on the connection between plant health and quality, with a particular focus on solutions to reversing harmful Citrus Greening, like Elemental Enzymes’ Vismax. Learn more about this episode on the Crusonia website.
Elemental Enzymes co-founder Brian Thompson will be joined by Vonnie Estes, VP of Technology at Produce Marketing Association, for an in-depth discussion on the connection between plant health and the quality, health, and taste of food, with a particular focus on solutions to reversing harmful Citrus Greening.
Of particular interest in this conversation will be how Elemental Enzyme’s field-proven, patented peptide solution Vismax is showing promise in reversing Citrus Greening which is negatively impacting the citrus industry and citrus quality from grove to grocer.
For Immediate Release – St. Louis, Missouri – August 11, 2020 – Elemental Enzymes, a St. Louis biotechnology firm, has obtained the first patent for a natural peptide solution that is field-proven to treat Citrus Greening disease. Capable of killing healthy citrus trees in less than five years, this bacterial disease has impacted fruit yields by more than 40 percent on citrus crops such as oranges causing more than $400M in grower losses annually with the financial impact reaching from grove to grocer.
Elemental Enzymes has developed, extensively field-tested and patented a naturally occurring peptide solution with the potential to deliver relief to the grove, and hope to the grower, while also enabling the industry to continue to affordably meet consumer demand for a wide range of citrus products.
This patented discovery by Elemental Enzymes CEO Dr. Brian Thompson culminated from the research of over 70 potential products on infected groves in Florida. The solution, named Vismax, is readying for commercialization and will reach market within the next few years.
Forty-five replicated field trials over the past four years have demonstrated that Vismax increases yield, reduces infection levels and accelerates tree recovery across Florida. Trials conducted throughout 2018 and 2019 showed a 19–25 percent increase of fresh fruit value on treated trees. In addition, Vismax-treated trees exhibited pronounced plant recovery from Citrus Greening symptoms, including a 95 percent reduction in Citrus Greening causing bacteria within eight weeks.
Vismax has been tested on over 10 citrus varieties and proven effective on the big three in Florida: oranges, grapefruits and tangerines. Dr. Thompson is optimistic about the sustainable impact of the patented, naturally occurring peptide solution and its promise to restore tree health and grower revenue. “The project we’ve undertaken triggers a powerful long-term effect in the plant to defend itself against bacterial and fungal diseases. And, since it does not directly target microbes, there is little to no risk of antimicrobial resistance building over time with no adverse impacts to fruit taste or appearance possible with alternative treatments.”
Elemental Enzymes Senior Scientist and head of Biochemical Pesticides, Dr. Michelle Leslie, adds “Using natural, non-toxic peptides to turn on the plant’s immune system is effective for fighting a wide range of plant infections, and a safer alternative to the widespread use of antibiotics that threaten ecosystems and human health. It’s striking to see the effect a small peptide can have on such heavily infected trees.”
And, the impact of this small peptide may reach well beyond the grove. Further Elemental Enzymes research shows similarly positive results on diseases in a broad range of row and specialty crops, including apples, almonds and grapes.
About Elemental Enzymes
Elemental Enzymes is catalyzing the future of agriculture with innovative, cross-disciplinary scientific solutions to complex problems impacting commercial agriculture. Elemental Enzymes creates enzyme, peptide and natural solutions that improve nutrient uptake, water management, plant health and yield. Elemental Enzymes has filed 140 patents and has 10 commercialized products with an additional 9, including this Citrus Greening solution, pending commercialization. Elemental Enzymes is located at 1685 Galt Industrial Blvd., St. Louis, MO 63132, and online at https://elementalenzymes.com/.
CONTACT: Stacie Schumer
Mizzou researchers’ discoveries launch businesses that move science to the market. Article from Mizzou News
Katie Thompson, BS ’04, PhD ’11, has all the good problems that being a scientist-entrepreneur brings — juggling an overload of current work, along with expansion; planning; marketing; and trying to solve the urgent problem of a greening disease that’s sweeping through Florida citrus groves. She’s in the midst of remodeling the St. Louis plant that houses Elemental Enzymes, the company she and her husband, Brian, MS ’08, founded in 2011 with Ashley Siegel, PhD ’11. The company also has a field research station in Columbia and employees in Jacksonville, Florida, and Australia. Now holding some 17 agriculture patents, the company got its start in the university’s Life Science Business Incubator, which not only provided initial lab space but also helped it write a business plan and raise funds from investors.
The 40-employee firm, focused on seed treatments and plant health, needs more room. Figuring out the logistics lands on her to-do list.
“When you’re an entrepreneur, there’s always so much more work going forward,” says Thompson, who grew up in Jefferson County in Missouri and earned her doctorate at Mizzou in cellular and molecular biology. “We never suffer from a lack of work.”
Credit the University of Missouri’s long-standing emphasis on research with helping to launch fledgling companies like Elemental Enzymes. Now, an ambitious five-year plan seeks to double the amount of federal and commercial research dollars on campus by 2023 — to $410 million.
Founders of Elemental Enzymes are, from left, Katie Thompson, Brian Thompson and Ashley Siegel. Photo by Bill Greenblatt.
The overarching goal is to underscore the university’s mission to benefit society.
“We’re trying to boost economic development for Missouri while addressing the world’s challenges in food, water and health,” says Jeff Sossamon, assistant director of strategic communications in MU’s Office of Research and Economic Development.
The effort paid off in dramatic fashion last year, with $48 million more flowing into the campus from federal grants and corporate partnerships, a healthy 29 percent increase over the $205 million in research funding in the prior year.
“There’s been really good buy-in across the campus,” says Lisa Lorenzen, who leads efforts to commercialize faculty innovations in Mizzou’s Technology Advancement Office. “The federal support we bring in creates hundreds, if not thousands, of jobs.”
ThermAvant Technologies’ Burnout mugs use space technology to bring hot beverages to a drinkable temperature and keep them there for hours.
One job-creating success is a Columbia company ThermAvant Technologies and its spinoff ThermAvant International. Founded by a mechanical engineering professor and an entrepreneur, ThermAvant specializes in heat-transfer, aviation and energy technologies supported with grants from the U.S. Department of Defense and the Missouri Technology Corp. ThermAvant International sells consumer products such as Burnout, a temperature-regulating travel mug.
The university’s research push also brings in millions of dollars — and in some years tens of millions of dollars — from licensing of researchers’ patented discoveries. Bill Turpin, president of the Missouri Innovation Center, which manages the MU Life Science Business Incubator, notes that one-third of the licensing fees go to the inventors, with other portions going to the department that housed the research, legal fees and to support the university’s general research programs. “There’s usually a seven-year lag time between creation and when money arrives,” he says.
Beyond jobs and income, university research is improving lives with medical and engineering advances. One start-up created in 2018 using technology licensed from the university is Intelligent Respiratory Devices. It uses premature babies’ own respiratory patterns to regulate the supplemental oxygen they need. Roger Fales, associate professor in the mechanical and aerospace engineering department, one of the three MU inventors of the technology, says his research was motivated by the possibility of saving tiny lives.
“This technology learns from the baby how to regulate oxygen,” Fales explains. “Too little can cause brain or tissue damage. Too much can lead to blindness. Nurses can do it manually, but this takes the workload off, and there’s initial hope for superior health care outcomes.”
Mizzou’s support for his research makes the nights and weekends he devotes to this invention seem worth it. “The university has been there from the beginning with grants,” he says.
As Lorenzen notes: “The faculty is not in it for the money. They really do want to make a difference.”
To bring these successes from the lab bench to the bedside has taken new efforts campuswide.
The five-year research plan not only solicits yearly roadmaps from each of MU’s deans on how to modernize laboratories and support research faculty but also energizes how the university acquires federal grants and industry partners. An Office of Research Advancement helps reduce the administrative burden of shepherding lab discoveries to commercial success.
Brainstorming sessions on campus — Big Ideas Labs — have been set up to push collaborative research across disciplines, Sossamon notes. “We get people to spend an entire day in a room with the goal of meeting one funding opportunity.” In a recent session, engineers, computer scientists and plant scientists were so animated by the collaboration that, instead of a single idea, they hammered out four proposals to submit for a single grant opportunity. “They came up with creative ways to use artificial intelligence drones to address farming problems with precision agriculture,” he says. “The collaboration means more bang for the buck.”
Mizzou also has boosted continuing education for faculty, students and postdoctoral candidates. New hires are expected to elevate MU’s research faculty by 300 people by 2023. “We’ve already landed some world-class researchers,” Turpin says, “and there’s a bonus because they bring along any federal grants they were working on.”
Research by MU professors Fu-hung Hsieh and Harold Huff helped launch Beyond Meat, a company whose clients now include KFC.
A new online community, Missouri StartupTree, connects faculty and student innovators with businesses, mentors and investors. University entrepreneurs benefit from new fast-track licensing assistance and aid in determining how to commercialize their discoveries.
Major start-ups also draw on the expertise of Missouri’s research faculty to further their commercial success. Beyond Meat, with its well-known investors Bill Gates and Leonardo DiCaprio, tapped the expertise of MU professors Fu-hung Hsieh and Harold Huff to launch the company now producing the well-received Beyond Burger sold widely in grocery stores, schools and restaurants. Its manufacturing site in Columbia expanded to 100,000 square feet, from 30,000, in 2018, generating some 250 new jobs in mid-Missouri. The company also brought “a big influx” of licensing income to the university last year, Turpin says.
Gabor Forgacs, the scientific founder of Organovo, a company using cells to build living tissues, is an emeritus physics professor in the College of Agriculture, Food and Natural Resources. The firm, engaged in organ printing and drug testing on blood vessels, now is traded on the Nasdaq Stock Market.
Similarly, research by Dongsheng Duan, the Margaret Proctor Mulligan Professor in Medical Research, has been licensed by Solid BioSciences, a Cambridge, Massachusetts, company that is racing to solve the mystery of Duchenne muscular dystrophy. Duan also serves on the company’s scientific advisory board.
Solid Biosciences has licensed research by Dongsheng Duan in the quest to cure Duchenne muscular dystrophy. Photo by Justin Kelley.
In addition to matching corporations with the right MU faculty, students also are receiving extra attention in finding commercial outlets for their research. Entrepreneur Quest, an annual contest sponsored by the University of Missouri System, gives student entrepreneurs a chance to win seed funding for their ventures.
The 2019 winner, veterinary student Libby Martin, invented a collar for pregnant cows that alerts ranchers in real time when birth is imminent. Because 10 percent of calves die during labor, often because ranchers arrive too late to help, her invention could lead to big cost savings for animal agriculture.
She won $30,000 for her “Fitbit for cows,” and her firm, Calving Technologies, already is testing prototypes in the field. “There is an unbelievable amount of resources here for students trying to do start-ups,” Martin says.
Veterinary student Libby Martin devised collars that let ranchers know when pregnant cows are about to deliver, reducing calf mortality. Photo by Karen Clifford.
Precision health care is a big focus of the research push, as are radiopharmaceuticals and agricultural science. Next year, a NextGen Precision Health Institute will open, directing increased attention to cancer and vascular and brain diseases. All are leading causes of death for Missourians.
Medical appliances and drug discoveries are large parts of the 800 patents that university faculty created. “The ideas in our [research] portfolio will be part of the next decades’ great advancements,” Lorenzen says.
Research has a long and valued history at MU. Back in 1876, for instance, state entomologist Charles Valentine Riley helped save the French wine industry by grafting French vines onto more disease-resistant American grape roots. The veterinary science department set up the country’s first vaccine virus lab in 1885, which was followed three years later by a pioneering Agricultural Experiment Station. The U.S. Congress was so impressed by the university’s soil erosion research in 1917 that it created field stations across the country.
A vision of the importance of nuclear energy pushed the university to transform the site of a former polo field into the nation’s largest campus-based nuclear reactor in 1966. Faculty and students in multiple colleges use the now 10-megawatt facility, which anchors MU’s Research Commons.
In the following decades, the Mizzou steadily established range of research centers. Campus now houses 11 specialized centers, termed research cores, working on DNA, information research, immunobiology, X-ray microanalysis and other cutting-edge subjects.
Directing Mizzou’s research battle plan is Mark McIntosh, vice chancellor and head of the Office of Research and Economic Development. Also on the frontlines is Turpin, whose MU Life Science Business Incubator continues to house Elemental Enzymes’ field research. “Mizzou did a lot to help us,” says Thompson, who notes that the company’s first two patents were created with the university. Elemental Enzymes is now working on a protein that boosts the immune system of plants, allowing crops to fight diseases without using fungicides or other chemicals. The discovery is making its way through approvals at the U.S. Environmental Protection Agency. “It’s a potential game-changer,” she notes.
Thompson has returned to campus to encourage students to follow her and her husband’s entrepreneurial path. “I truly hope that even more companies can start out at Mizzou,” she says. “It’s a great way to grow your research.”
To read more articles like this, become a Mizzou Alumni Association member and receive MIZZOU magazine in your mailbox. Click here to join.